Synergistic Role of Activated CD4 Memory T Cells and CXCL13 in Augmenting Cancer Immunotherapy Efficacy

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Mar 18

PMID 38495207

Authors

Wenhao Ouyang

Qing Peng

Zijia Lai

Hong Huang

Zhenjun Huang

Xinxin Xie

Ruichong Lin

Zehua Wang

Herui Yao

Yunfang Yu

Affiliations

Soon will be listed here.

Abstract

The development of immune checkpoint inhibitors (ICIs) has significantly advanced cancer treatment. However, their efficacy is not consistent across all patients, underscoring the need for personalized approaches. In this study, we examined the relationship between activated CD4 memory T cell expression and ICI responsiveness. A notable correlation was observed between increased activated CD4 memory T cell expression and better patient survival in various cohorts. Additionally, the chemokine CXCL13 was identified as a potential prognostic biomarker, with higher expression levels associated with improved outcomes. Further analysis highlighted CXCL13's role in influencing the Tumor Microenvironment, emphasizing its relevance in tumor immunity. Using these findings, we developed a deep learning model by the Multi-Layer Aggregation Graph Neural Network method. This model exhibited promise in predicting ICI treatment efficacy, suggesting its potential application in clinical practice.

References

Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z . Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Netw Open. 2020; 3(4):e202149. PMC: 7139278. DOI: 10.1001/jamanetworkopen.2020.2149. View

Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View

Li H, van der Leun A, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A . Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell. 2019; 176(4):775-789.e18. PMC: 7253294. DOI: 10.1016/j.cell.2018.11.043. View

Bell E, Westermann J . CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol. 2008; 29(9):405-11. DOI: 10.1016/j.it.2008.06.002. View

Dileepan T, Malhotra D, Kotov D, Kolawole E, Krueger P, Evavold B . MHC class II tetramers engineered for enhanced binding to CD4 improve detection of antigen-specific T cells. Nat Biotechnol. 2021; 39(8):943-948. PMC: 10666075. DOI: 10.1038/s41587-021-00893-9. View

Veatch J, Lee S, Shasha C, Singhi N, Szeto J, Moshiri A . Neoantigen-specific CD4 T cells in human melanoma have diverse differentiation states and correlate with CD8 T cell, macrophage, and B cell function. Cancer Cell. 2022; 40(4):393-409.e9. PMC: 9011147. DOI: 10.1016/j.ccell.2022.03.006. View

Lim H, Kim C . Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue. J Immunol. 2007; 179(11):7448-56. DOI: 10.4049/jimmunol.179.11.7448. View

Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M . The interaction of CD4 helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat Cancer. 2022; 3(3):303-317. DOI: 10.1038/s43018-022-00338-5. View

Strickland M, Alvarez-Breckenridge C, Gainor J, Brastianos P . Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity. Cancer Discov. 2022; 12(5):1199-1216. PMC: 11440428. DOI: 10.1158/2159-8290.CD-21-0976. View

10.

Ahrends T, Borst J . The opposing roles of CD4 T cells in anti-tumour immunity. Immunology. 2018; . PMC: 6050207. DOI: 10.1111/imm.12941. View

11.

Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P . Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut. 2011; 61(8):1163-71. PMC: 3388728. DOI: 10.1136/gutjnl-2011-300970. View

12.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

13.

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

14.

Qiu J, Li X, He Y, Wang Q, Li J, Wu J . Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. J Transl Med. 2022; 20(1):613. PMC: 9783967. DOI: 10.1186/s12967-022-03836-3. View

15.

Kather J, Heij L, Grabsch H, Loeffler C, Echle A, Muti H . Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Cancer. 2021; 1(8):789-799. PMC: 7610412. DOI: 10.1038/s43018-020-0087-6. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Caushi J, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E . Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021; 596(7870):126-132. PMC: 8338555. DOI: 10.1038/s41586-021-03752-4. View

18.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

19.

Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q . CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer. 2021; 9(1). PMC: 7813306. DOI: 10.1136/jitc-2020-001136. View

20.

Rose T, Weir W, Mayhew G, Shibata Y, Eulitt P, Uronis J . Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021; 125(9):1251-1260. PMC: 8548561. DOI: 10.1038/s41416-021-01488-6. View